SeptiCyte RAPID demonstrated superior performance compared to procalcitonin and C-reactive protein in detecting sepsis among critically ill patients with hospital-acquired infections.
Johns Hopkins researchers develop multi-analyte assay combining tumor DNA, mutations, and immune cell signatures for central nervous system cancer diagnosis.
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Multi-disciplinary cancer center will implement Halo Intelligence platform to enhance precision oncology capabilities across Pacific Northwest.
Clinical labs help drive early HIV detection and support efforts to prevent its spread.
The new noninvasive prenatal test addresses testing gaps when biological fathers are unavailable for carrier screening by analyzing fetal DNA from maternal blood samples.
Smartphone-based system aims to enable patient self-application and remote monitoring of contact dermatitis tests, potentially expanding access to specialized care.
Lipoprotein(a), or Lp(a), is a genetically determined and under-recognized cardiovascular disease risk factor.
A Rutgers research director outlines clinical applications and limitations of the new diagnostic tool while highlighting the need for specialist interpretation.
It's essential to integrate point-of-care testing devices cautiously alongside traditional laboratory tests to ensure robust diabetes management.
With the acquisition, Quest will now provide dialysis lab testing for independent clinics that were previously served by Spectra Laboratories.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter study found that early sepsis risk testing at triage led to more ED discharges and lower inpatient bed use without compromising patient safety.